- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The following median (IQR) steady state population pharmacokinetic parameters were found in 38 children, 2-13 years of age (median 21 kg and 6,3 years), after oral doses of 2.5 mg/kg every other day (Kreeftmeijer-Vegter et al. 2015):
| Cmax | 438.3 (316,5 – 621.8) ng/ml |
| Tmax | 1.7 (1.3 – 2.0) hour |
| t½ | 2.6 (2.1 – 3.7) hour |
| Cl/F | 44 (RSE 8.5) l/hour/70 kg |
| Vd/F | 236 (RSE 13.3) l/70 kg |
IQR = interquartile range
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Steroid-sensitive nephrotic syndrome |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Leucopenia and gastrointestinal upsets are described. Rare cases of cutaneous vasculitis have been described with levamisole therapy.(KDIGO guideline)
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Levamisole has been associated with agranulocytosis. Agranulocytosis is usually accompanied by flu-like symptoms (fever, shivering), but it can also be asymptomatic.Flulike symptoms can also occur without aranulocytosis.Patients and parents should contact their physician whenever flu-like symptoms occur, It's recommended to check the blood count every 4 weeks. (old SmPC Ergamisol)
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Benzimidazole derivatives | ||
|---|---|---|
| P02CA03 | ||
| P02CA01 | ||
| Tetrahydropyrimidine derivatives | ||
|---|---|---|
| P02CC01 | ||
| Avermectines | ||
|---|---|---|
| P02CF01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Kreeftmeijer-Vegter AR, et al , Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. , Br J Clin Pharmacol. , 2015, 80(2), 242-252
- KDIGO , Clinical Practice Guideline for Glomerulonephritis, Kidney Int, 2012, Vol 2(Suppl 2), 139-274
- Jansen Cilag BV, SmPC Ergamisol (RVG 14850) 12 juni 2002 - license revoked by manufacturer
- Elmas, A. T., et al, Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome, Int Urol Nephrol, 2013, 45 (4), 1047-55
- Gruppen, M. P., et al, A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome, Kidney Int, 2018, 93 (2), 510-518
- Pravitsitthikul, N., et al, Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children., Cochrane Database Syst Rev, 2013, (10), Cd002290
- IBM Corporation. , 2020 Levamisole. In: In depth answers , Available from: www.micromedexsolutions.com Subscription required to view., [database in the internet]. Greenwood village (CO):
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
